Ocumension Therapeutics held its Annual General Meeting (AGM) on 30 June 2026 in Shanghai. All ordinary resolutions were approved by poll, clearing every motion with support ranging from 97.10% to 100.00% of votes cast.

Key approvals • 2025 audited financial statements and reports: 100.00% in favour (240.60 million shares). • Director matters: – Acts of Director Zhenyu Zhang ratified (100.00% support). – Re-election of Dr. Lian Yong Chen (98.72%), Mr. Yanling Cao (99.93%) and Mr. Zhenyu Zhang (99.94%). – Election of Ms. Beibei Zhuang as Independent Non-Executive Director (INED) with 100.00% support. – Board authorised to set director remuneration (99.97%). • Re-appointment of Deloitte Touche Tohmatsu as auditor: 99.06% support. • Share mandates: – 20% general issuance mandate: 98.14% support. – 10% share repurchase mandate: 100.00% support. – Mandate extension (repurchase plus issuance): 97.10% support. • Refresh of equity incentive limits: – Scheme Mandate Limit (8%): 98.39% support. – Service Provider Sublimit (0.8%): 97.35% support.

Director changes • Ting Yuk Anthony Wu retired as INED and stepped down as chairman of the Audit Committee and member of the Remuneration and Nomination Committees. • Beibei Zhuang, aged 45, was elected INED and appointed chairwoman of the Audit Committee and member of the Remuneration and Nomination Committees. Zhuang brings over 15 years’ audit experience, most recently as an audit partner at BDO China. Her annual director’s fee is HK$200,000 under a three-year term.

Share capital and voting base The company had 0.82 billion issued shares (excluding 20.95 million treasury shares) eligible to vote. The trustee holding 3.85 million unvested shares under employee schemes abstained from voting in accordance with listing rules. Computershare Hong Kong Investor Services acted as scrutineer.

Board composition after the AGM • Executive Directors: Ye Liu, Dr. Zhaopeng Hu • Non-Executive Directors: Dr. Lian Yong Chen (Chairman), Mr. Yanling Cao, Dr. Qin Xie • Independent Non-Executive Directors: Ms. Beibei Zhuang, Mr. Yiran Huang, Mr. Zhenyu Zhang

All approvals position Ocumension Therapeutics to continue its governance and capital management activities for the coming year.